Study supports TIM-3 as therapeutic target for Alzheimer’s disease
March 15, 2024
Recent studies have identified HAVCR2, which encodes immune checkpoint molecule TIM-3 (T-cell immunoglobulin mucin receptor 3), as a risk gene for late-onset Alzheimer’s disease (AD).